Elanix Biotechnologies AG reported audited consolidated earnings results for the six months ended June 30, 2017. For the six months, the company reported total revenue of EUR 77,847 compare to EUR 0 for the same period a year ago. Operating loss was EUR 1,976,839 compare to EUR 940,000 for the same period a year ago. Operating loss before financial expenses was EUR 2,036,000 compare to EUR 940,000 for the same period a year ago. Net loss was EUR 1,677,000 or EUR 0.26 per diluted share compare to EUR 784,000 or EUR 0.15 per diluted share for the same period a year ago.

For the financial year 2017, the company reaffirmed its financial guidance. The company confirms its expectations for total revenue of EUR 300,000 to EUR 500,000.